Crucell focuses on developing and marketing vaccines and antibodies against a range of infectious diseases. The Company currently has a product portfolio of vaccines against influenza, hepatitis A, hepatitis B and typhoid fever.

Vaccines play a vital role in protecting against disease and have contributed significantly to the improvement of global public health in the twentieth century. Smallpox was eradicated through the use of vaccines, and polio is well on its way to eradication. Significant developments include the introduction of combination vaccines and the development of new vaccine technologies that may advance vaccine development.

In this section, you will find information about Crucell’s vaccine products and comprehensive information about the diseases each of these vaccines is designed to prevent.

Crucell’s vaccines:

• Hepavax-Gene^® - the recombinant hepatitis B vaccine
• Quinvaxem™ - the fully-liquid vaccine for protection against five important childhood diseases 
• Epaxal^® - the only aluminium-free hepatitis A vaccine
• Vivotif^® - the only oral anti-typhoid vaccine
• Inflexal^® V – the virosomal adjuvanted influenza vaccine for all age groups
• MoRu-Viraten^® - a safe, well-tolerated and effective vaccine for protection against measles and rubella in children, adolescents and adults
• Dukoral® - the only internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera

Vaccine Discovery

Development Pipeline

Technology